Enovix Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Enovix Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $31.82M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $23.07M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.64M | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | $6.20M | Feb 25, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $31.82M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $23.07M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.64M | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | $6.20M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $0 | Mar 1, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $6.11M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | ($2.05M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($55.42M) | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | ($17.04M) | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | ($1.97M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($3.38M) | Mar 1, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($156.74M) | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | ($222.24M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($214.07M) | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | ($51.62M) | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | ($125.87M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($39.65M) | Mar 1, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($177.25M) | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | ($242.67M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($230.26M) | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | ($131.98M) | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | ($69.52M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($23.53M) | Mar 1, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $110.33M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $124.51M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $88.39M | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | $58.05M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $37.85M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $14.44M | Mar 1, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $73.03M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $74.31M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $79.01M | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | $51.97M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $29.71M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $5.71M | Mar 1, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($95.29M) | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | ($108.63M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($104.64M) | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | ($82.74M) | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | ($51.31M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($20.05M) | Mar 1, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $18.22M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $76.19M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $61.80M | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | $36.21M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $43.58M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $26.95M | Mar 1, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $878.98M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $527.17M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $564.30M | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | $440.59M | Feb 29, 2024 |
| FY2022 | Jan 2, 2022 | $482.57M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $64.96M | Mar 25, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $604.96M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $277.77M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $303.20M | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | $84.16M | Feb 29, 2024 |
| FY2022 | Jan 2, 2022 | $156.45M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $28.75M | Mar 25, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $271.21M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $246.74M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $258.15M | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | $356.43M | Feb 29, 2024 |
| FY2022 | Jan 2, 2022 | $326.12M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $36.22M | Mar 1, 2023 |
| FY2022 | Dec 31, 2019 | $2.98M | Mar 1, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $12.22M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $12.22M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $12.10M | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | $0 | Feb 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | ($977.83M) | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | ($821.09M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($598.85M) | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | ($384.77M) | Feb 29, 2024 |
| FY2022 | Jan 2, 2022 | ($333.15M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($207.28M) | Mar 25, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $106.01M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $272.87M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $233.12M | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | $322.85M | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | $385.29M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $29.14M | Mar 1, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $519.50M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | $169.99M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $170.70M | Feb 25, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | 0 | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Jan 1, 2023 | 0 | Feb 25, 2025 |
| FY2023 | Jan 2, 2022 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | 216.56M | Feb 25, 2026 |
| FY2025 | Dec 29, 2024 | 190.56M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 167.39M | Feb 25, 2025 |
| FY2023 | Jan 1, 2023 | 157.46M | Feb 29, 2024 |
| FY2022 | Jan 2, 2022 | 152.27M | Mar 1, 2023 |
| FY2023 | Jul 14, 2021 | 145.25M | Feb 29, 2024 |
| FY2023 | Jul 13, 2021 | 563.32M | Feb 29, 2024 |
| FY2021 | Dec 31, 2020 | 100.02M | Mar 25, 2022 |